Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...103104105106107108109110111112113...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Microsatellite Instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO Biomarker:  The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status. (Pubmed Central) -  Apr 24, 2019   
    ...Monoclonal antibodies against EGFR (cetuximab and panitumumab) represent a major step in the treatment of mCRC...Checkpoint inhibitors, such as anti-PD1 (nivolumab and pembrolizumab) and anti-CTLA-4 (ipilimumab) antibodies have already been developed and applied in mCRC patients with MSI-H phenotype...Both combinatorial approaches reduce cell viability through the induction of apoptotic cell death. The findings of this study point out the importance of different approach for the treatment of BRAF mutant metastatic colorectal cancers based on their microsatelite instability phenotype.
  • ||||||||||  Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Trial completion, Trial completion date, Metastases:  Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 23, 2019   
    P1/2,  N=156, Completed, 
    The findings of this study point out the importance of different approach for the treatment of BRAF mutant metastatic colorectal cancers based on their microsatelite instability phenotype. Active, not recruiting --> Completed | Trial completion date: Jul 2019 --> Feb 2019
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=100, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Aug 2019 --> Aug 2022 | Trial primary completion date: Aug 2019 --> Aug 2022
  • ||||||||||  napabucasin (BBI608) / Sumitomo Pharma
    Trial primary completion date, Metastases:  A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=203, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  ERMES: Erbitux MEtastatic Colorectal Cancer Strategy Study (clinicaltrials.gov) -  Apr 19, 2019   
    P3,  N=600, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Aug 2020 | Trial primary completion date: Nov 2018 --> Dec 2019
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. (Pubmed Central) -  Apr 18, 2019   
    ...Three different contrast agents were compared for their tumor targeting effectiveness: non-targeted nanoparticles, nanoparticles conjugated with full-sized anti-EGFR antibodies (cetuximab), and nanoparticles conjugated with a single-domain llama-derived anti-EGFR antibody, which is smaller than the cetuximab, but has a lower binding affinity...This study provides useful insight into targeted nanoparticle design and demonstrates that nanoparticle contrast agents can be used to detect tumor receptor overexpression. Combining receptor status data with traditional imaging characteristics has the potential for better differentiation of malignant lung tumors from benign lesions.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal, Combination therapy:  Cetuximab in combination with chemoradiotherapy for nasopharyngeal carcinoma: A meta-analysis. (Pubmed Central) -  Apr 18, 2019   
    Combining receptor status data with traditional imaging characteristics has the potential for better differentiation of malignant lung tumors from benign lesions. The combination of cetuximab and CCRT was more effective for NPC than CCRT alone and had no serious side effects.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Is EGFR really a therapeutic target in head and neck cancers? (Pubmed Central) -  Apr 18, 2019   
    Even though there was some success with Cetuximab, work with other EGFR inhibition has not been very fruitful and not really shown any promise. Mechanism of action of Cetuximab could be immune-mediated rather than EGFR inhibition and EGFR may not necessarily be a therapeutic target in SCCHN.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Biomarker, Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO Biomarker:  Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go? (Pubmed Central) -  Apr 18, 2019   
    ...Nevertheless, to date platinum-based cytostatic agents remain the first line choice and targeting the epidermal growth factor-receptor (EGFR) with combined cetuximab and radiation therapy remains the only targeted therapy approved in the curative setting...Nivolumab and pembrolizumab, two anti-PD-1 antibodies, were the first agents shown to improve overall survival for patients with metastatic/recurrent tumors in recent years...A robust set of biomarkers will be an inevitable tool for future individualized treatment approaches including radiation dose de-escalation and escalation strategies. This review aims to summarize achieved goals, the current status and future perspectives regarding targeted therapies and ICI in the management of SCCHN.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO Biomarker:  Selecting treatment options in refractory metastatic colorectal cancer. (Pubmed Central) -  Apr 18, 2019   
    Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. (Pubmed Central) -  Apr 17, 2019   
    Moreover, ND-PTX-Cet induced the mitotic marker protein phospho-histone 3 (Ser10) and apoptotic protein active-caspase 3 for mitotic catastrophe and apoptosis. Taken together, this study demonstrated that the co-delivery of PTX and Cet by ND enhanced the effects of mitotic catastrophe and apoptosis in vitro and in vivo, which may be applied in the human CRC therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Optimizing Glioma Detection using an EGFR-Targeted Fluorescent Affibody. (Pubmed Central) -  Apr 14, 2019   
    ...Uptake kinetics of EGFR-targeted fluorescent Affibody (ABY-029) were studied with a view toward optimizing efficacy of tumor detection in a glioma as a function of both delivered dose and concurrent administration of unlabeled cetuximab (an EGFR antagonist)...According to FDA, the microdose of protein products is considered ≤ 30 nanomoles due to its difference in molecular weight as compared to synthetic drugs. This observation indicates that glioma detection will be optimal if the ABY-029 dose exceeds the 'microdose' value.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  A Case of Advanced Sigmoid Colon Cancer That Was Resected after Chemoradiation Therapy Following Ineffective Chemotherapy (Pubmed Central) -  Apr 13, 2019   
    Tumor shrinkage in the primary lesion was achieved after CRT; total pelvic exenteration with the removal of metastatic para-aortic lymph nodes was then performed 5 months after the first diagnosis. This case of locally distant advanced colon cancer in the pelvic cavity coexisting with resectable metastatic lesions suggested that CRTmight contribute to successful local treatment after the failure of preoperative chemotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  The alpha-Gal syndrome: new insights into the tick-host conflict and cooperation. (Pubmed Central) -  Apr 12, 2019   
    ...The conflict is characterized by the AGS that mediate delayed anaphylaxis to red meat consumption and certain drugs such as cetuximab, and immediate anaphylaxis to tick bites...Despite the growing diagnosis of AGS in all world continents, many questions remain to be elucidated on the tick proteins and immune mechanisms triggering this syndrome, and the protective response against pathogen infection elicited by anti-α-Gal antibodies. The answer to these questions will provide information for the evaluation of risks, diagnosis and prevention of the AGS, and the possibility of using the carbohydrate α-Gal to develop vaccines for the control of major infectious diseases.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Preclinical, Journal:  A novel real-time proximity assay for characterizing multiple receptor interactions on living cells. (Pubmed Central) -  Apr 11, 2019   
    Treated cells displayed 50% increased proximity signal, whereas the binding characteristics of the two antibodies were not significantly affected, implying an increase in EGFR-HER2 dimer level. These results demonstrate that real-time proximity interaction analysis enables determination of the interaction rate constants and affinity of two ligands while simultaneously quantifying their relative co-localization on living cells.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Clinical, Journal:  Efficacy and Prognostic Factors of Cetuximab Therapy in Treating KRAS or All RAS Wild-type Metastatic Colorectal Cancer (Pubmed Central) -  Apr 11, 2019   
    The median OS of the eight patients continuing cetuximab beyond first-line progression was 35.0(95%CI:23.6-46.4)months.Conclusions The efficacy of cetuximab for left-sided colorectal cancer was better than for right-sided colon cancer,and patients with all-RAS-WT have lower risk of progression than those with KRAS-only-WT. Patients benefiting from first-line cetuximab and continuing cetuximab beyond progression survive longer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Cetuximab-induced epidermolysis revealed by multiple erosions. (Pubmed Central) -  Apr 5, 2019   
    In conclusion, LDHB was identified as an important factor affecting cetuximab sensitivity using comprehensive proteome analysis for the first time. No abstract available
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Biomarker, Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. (Pubmed Central) -  Apr 5, 2019   
    The most promising clinical results have been obtained when m-TKIs are tested in combination with other therapies, including immunotherapy, or in mutation-defined subgroups of patients. The future success of m-TKIs will rely on identification, in preclinical models and clinical trials, of predictive biomarkers of response and mechanisms of innate and acquired resistance.